Rybrevant Faspro Wins FDA Priority Review as J&J Clears Talc Overhang
JNJ sits 57% above its 52-week low of $164.23.
Summary
The FDA granted Priority Review to Rybrevant Faspro for advanced head and neck cancer, a new catalyst not previously reported. This comes as J&J finalizes its $5.5B talc settlement, removing a major legal overhang, and shares rose ~3% after-hours. The EPS guidance cut to $10.86-$11.01, driven by the Firefly/Sail deals, was already known, but the combination of litigation resolution and a new regulatory milestone shifts the narrative. The Priority Review could accelerate a subcutaneous option in a high-need indication, adding a growth driver. Watch for the FDA decision date, which will be set with the filing acceptance.
At the time of this announcement, JNJ was trading at $258.35 on NYSE in the Life Sciences sector, with a market capitalization of approximately $617.8B. The 52-week trading range was $164.23 to $274.90. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.